{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T18:43:44Z","timestamp":1694112224237},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10637-018-0576-y","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T13:14:57Z","timestamp":1519132497000},"page":"513-516","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report"],"prefix":"10.1007","volume":"36","author":[{"given":"Michael W.","family":"van Kalleveen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maudy","family":"Walraven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathijs P.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"issue":"8","key":"576_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","volume":"116","author":"MB Davidson","year":"2004","unstructured":"Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ (2004) Pathophysiology, Clinical Consequences, and Treatment of Tumor Lysis Syndrome. Am J Med 116(8):546\u2013554.","journal-title":"Am J Med"},{"key":"576_CR2","doi-asserted-by":"crossref","unstructured":"Krishnan G, D\u2019Silva K, Al-Janadi A (2008) Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma. J Clin Oncol 26(14):2406\u20132408. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18467734","DOI":"10.1200\/JCO.2007.14.7603"},{"key":"576_CR3","doi-asserted-by":"crossref","unstructured":"Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B (2010) Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs 28(5):690\u2013693. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19547920","DOI":"10.1007\/s10637-009-9275-z"},{"key":"576_CR4","doi-asserted-by":"crossref","unstructured":"Nicholaou T, Wong R, Davis ID (2007) Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 369(9577):1923\u20131924. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17560435","DOI":"10.1016\/S0140-6736(07)60903-9"},{"key":"576_CR5","doi-asserted-by":"crossref","unstructured":"Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S, et al (2010) A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med 49(11):991\u2013994. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20519814","DOI":"10.2169\/internalmedicine.49.3153"},{"key":"576_CR6","doi-asserted-by":"crossref","unstructured":"Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127(1):3\u201311. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15384972","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"576_CR7","doi-asserted-by":"crossref","unstructured":"Howard SC, Jones DP, Pui C-H (2011) The tumor lysis syndrome. N Engl J Med 364(19):1844\u20131854. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21561350","DOI":"10.1056\/NEJMra0904569"},{"key":"576_CR8","doi-asserted-by":"crossref","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u2013245. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7249508","DOI":"10.1038\/clpt.1981.154"},{"key":"576_CR9","doi-asserted-by":"crossref","unstructured":"Parida S (2013) Clinical causality assessment for adverse drug reactions. Indian J Anaesth (3):57, 325\u2013356 Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23983309","DOI":"10.4103\/0019-5049.115608"},{"issue":"9","key":"576_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","volume":"56","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N (2017) Clinical pharmacokinetics and pharmacodynamics of Pazopanib: towards optimized dosing. Clin Pharmacokinet 56(9):987-997. https:\/\/doi.org\/10.1007\/s40262-017-0510-z","journal-title":"Clin Pharmacokinet"},{"key":"576_CR11","doi-asserted-by":"crossref","unstructured":"de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, et al (2015) Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib. Ther Drug Monit 37(3):331\u2013338. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25271729","DOI":"10.1097\/FTD.0000000000000141"},{"key":"576_CR12","doi-asserted-by":"crossref","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al (2009) Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clin Cancer Res 15(12):4220\u20134227. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19509175","DOI":"10.1158\/1078-0432.CCR-08-2740"},{"key":"576_CR13","doi-asserted-by":"crossref","unstructured":"Imbs D-C, Paludetto M-N, N\u00e9grier S, Powell H, Lafont T, White-Koning M, et al (2016) Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. Invest New Drugs 34(1):41\u201348. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26572909","DOI":"10.1007\/s10637-015-0304-9"},{"key":"576_CR14","unstructured":"CHMP. Annex I Summary of product characteristics. Cited 30 May 2017. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001141\/WC500094272.pdf"},{"key":"576_CR15","doi-asserted-by":"crossref","unstructured":"Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, et al (2013) Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 71(6):1635\u20131643. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23636448","DOI":"10.1007\/s00280-013-2164-3"},{"key":"576_CR16","doi-asserted-by":"crossref","unstructured":"Klein K, Zanger UM (2013) Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the \"Missing Heritability\" Problem. Front Genet. 4:12. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23444277","DOI":"10.3389\/fgene.2013.00012"},{"key":"576_CR17","doi-asserted-by":"crossref","unstructured":"Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, et al (2012) Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities. Drug Metab Dispos. 40(1):83\u201392. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21994437","DOI":"10.1124\/dmd.111.042259"},{"key":"576_CR18","doi-asserted-by":"crossref","unstructured":"Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M, et al (2012) PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo. Clin Pharmacol Ther 91(6):1044\u20131052. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22510778","DOI":"10.1038\/clpt.2011.336"},{"key":"576_CR19","doi-asserted-by":"crossref","unstructured":"Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, et al (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31(6):755\u2013761. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12756208","DOI":"10.1124\/dmd.31.6.755"},{"key":"576_CR20","doi-asserted-by":"crossref","unstructured":"Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, et al (2010) A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors. Clin Pharmacol Ther 88(6):818\u2013823. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20980999","DOI":"10.1038\/clpt.2010.199"},{"key":"576_CR21","doi-asserted-by":"crossref","unstructured":"Xu C-F, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, et al (2016) HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clin Cancer Res. 22(6):1371\u20131377. Cited 30 May 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26546620","DOI":"10.1158\/1078-0432.CCR-15-2044"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0576-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:20:52Z","timestamp":1678558852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0576-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0576-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"assertion":[{"value":"1 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Michael W. van Kalleveen declares that he has no conflict of interest. Author Maudy Walraven declares that she has no conflict of interest. Author Mathijs P. Hendriks declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent by patients and caregivers was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Approval for the short report was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}